565 related articles for article (PubMed ID: 30115483)
1. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
3. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
4. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
5. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
8. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
9. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
10. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract][Full Text] [Related]
11. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
12. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
13. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
14. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
18. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
20. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
